Russia’s second-largest oil producer Lukoil reached a tentative agreement on Thursday to sell the majority of its international assets to U.S. private equity firm Carlyle Group, as Western sanctions continue to push Russian energy companies to sell off their assets abroad.
Sanctions Pressure Drives Asset Sales
The companies did not disclose the value of the potential deal, which includes Lukoil’s oil and gas fields from Iraq to Mexico, thousands of petrol stations in 20 countries, and refineries in Bulgaria and Romania.
But the deal will not include Lukoil's interests in Kazakhstan. The company had previously stated the book value of its entire international business as $22 billion.
The sale follows U.S. sanctions on Lukoil and Rosneft in October 2025, Russia's two top oil producers, in response to the ongoing conflict in Ukraine.
On Wednesday, Kazakhstan separately submitted a bid to U.S. authorities to acquire Russian oil producers’ stakes in the country's energy projects.
The Race Isn’t Over: Approvals Pending, Rivals Waiting
Lukoil said that its agreement with Carlyle was conditional, not exclusive, and it would continue negotiations with other parties, which reportedly include Chevron Corporation (NYSE:CVX) and Quantum Capital Group, who are preparing a competing joint bid. ExxonMobil(NYSE:XOM) and Abu Dhabi’s International Holding Company have also previously expressed interest in acquiring the company’s international portfolio.
The negotiations became feasible in November when the U.S. Treasury Department authorized potential buyers to engage with Lukoil for the purchase of its foreign assets, which account for about 0.5% of global oil production.
Analysts say Lukoil's oil and gas output from its overseas operations is still expected to rise through the end of the decade, according to S&P Global, despite the asset sale.
Photo:Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.